A Phase I, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HB0017 Following a Single Dose in Adult Healthy Volunteers
Latest Information Update: 30 Jul 2021
At a glance
- Drugs HB 0017 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Huabo Biopharm
- 26 Jul 2021 Status changed from active, no longer recruiting to completed.
- 19 Feb 2021 Status has been changed to active, no longer recruiting.
- 11 Aug 2020 New trial record